CASI is a NASDAQ-listed biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products.

Our headquarter is in Beijing, China and we have joint venture subsidiary in Wuxi, China, and a branch office in Rockville, Maryland, USA.

Our goal is to establish a platform for launching medicines in the Greater China market with CASI’s experienced China-based regulatory and commercial competencies and proficient global drug development expertise.

We have a strong and growing pipeline of commercially available and clinical-staged drug candidates and continue to acquire assets at commercial and/or clinical development stages through in-license and acquisitions.